T umor cells can be specifically targeted using mAbs that bind to specific or overexpressed Ags on the tumor cell surface. Some of these mAbs can directly affect tumor growth or survival when their Fab portions are bound to their target, for example, trastuzumab targeting HER2/Neu. Some mAbs, however, target molecules that are not involved in tumor growth or survival. In most situations, however, mAbs bound to tumor cells enable the recruitment of phagocytic and cytotoxic immune cells bearing receptors for the Fc portion of IgG (FcgR). Activating FcgRs are indeed necessary for the protective effect of the mouse anti-gp75 mAb TA99 on the development of lung metastases of gp75-expressing B16F10 mouse melanoma cells (1) . The contribution of FcgRs in the context of a therapy using a combination of chemotherapy and anti-gp75 mAb treatment has, however, not been investigated.
Activating FcgRs in humans comprise FcgRI (CD64), FcgRIIA (CD32A), FcgRIIC (CD32C), and FcgRIIIA (CD16A), whereas in mice, FcgRI, FcgRIII, and FcgRIV exist. All mouse activating FcgRs require the association of the FcRg subunit to be expressed and functional at the cell surface. The generation of FcRg 2/2 mice allowed for the discovery that activating FcgRs contribute primarily to the protective effect of mAb TA99 on B16 lung metastases (1) . Since then, FcgRI 2/2 mice (2, 3), FcgRIII 2/2 mice (4), and FcgRIV 2/2 mice (5) have been reported; however, studies that have used these mice to identify the activating FcgR(s) responsible for the protective effect of mAb TA99 on B16 lung metastases report contradictory results. Whereas Nimmerjahn et al. (6) described a contribution of FcgRIV, but neither FcgRI nor FcgRIII, Bevaart et al. (7) described a mandatory role for FcgRI, but no detectable contribution of FcgRIII or, by deduction, of FcgRIV. These opposing results may be attributable to differences in techniques used to measure tumor load: Nimmerjahn et al. (6) counted the total number of lung surface metastases, whereas Bevaart et al. (7) only in single mAb therapy, but also in combination therapy with cyclophosphamide (CTX). Moreover, we identified a significant and unexpected contribution of FcgRIII, confirmed the contribution of FcgRI, and excluded any contribution of FcgRIV to TA99 mAb therapy. (10) . All mice were used at 6-10 wk of age. A total of 1 3 10 6 B16 cells were injected i.v. on day 0. Where indicated, mice were injected with mAb TA99 (200 mg) or isotype control i.p. on days 0, 1, 2, 4, 7, and 9; CTX (100 mg/kg) i.p. on day 0; anti-FcgRIV (mAb 9E9, hamster IgG, 200 mg), anti-FcgRIII (mAb 275003, rat IgG2a, 100 mg), or respective isotype controls i.v. on days 0, 2, 4, and 6. Mice were shaved, anesthetized, and injected i.p. with 3 mg luciferin to acquire bioluminescence on the whole mouse. Alternatively, explanted lungs were exposed to luciferin (50 ml at 15 mg/ml) 2 min before bioluminescence acquisition (IVIS 100; Caliper Life Sciences), with settings of 2 min exposure time and medium binning. Total photon flux (photons/seconds) was calculated using Living Image software. Mouse protocols were approved by the Animal Care and Use Committees of Paris, France.
Materials and Methods

Reagents and flow cytometry
In vitro assays
For bioluminescence detection, B16-Luc2 + cells (5000/well) were added to a black 96-well plate, incubated with D-luciferin (150 mg/ml), and bioluminescence acquired.
Statistical analyses
Data were analyzed using Student t test (NS: p . 0.05, *p , 0.05, **p , 0.01, ***p , 0.001). Error bars correspond to SEM. In vivo data were analyzed using two-way ANOVA with Bonferroni test.
Results and Discussion
An i.v. injection of B16-F10 cells leads to lung metastases of very different sizes (Fig. 1A, left panel) . Notably, metastases developed also inside the lung parenchyma (Fig. 1A , right panel), a parameter that was not considered in previous studies (6, 7) . To analyze the contribution of FcgR to the B16-TA99 metastasis immunotherapy model with an accurate measure of tumor load, we took advantage of a B16-F10 variant expressing the enhanced firefly luciferase (luc2) that allows assessment of tumor growth by bioluminescence. The expression of luc2 in B16-F10 cells led to photon release in the presence of luciferin but did not alter the expression of gp75 (Supplemental Fig. 1A) . In vitro B16-luc2 + cell growth was not affected by anti-gp75 mAb TA99 whether bound or aggregated at the cell membrane (Supplemental Fig. 1B) , as expected (11) . When injected i.v., B16-luc2 + cells formed metastases specifically in the lung that could be noninvasively monitored in vivo and quantified over time by bioluminescence. Performing the same analysis on explanted lungs from the same mice, however, increased the sensitivity 20-fold (Supplemental Fig. 1C ). Subsequent analyses were therefore performed on explanted lungs at day 11 postinjection of B16-luc2 + cells.
B16-luc2
+ metastases formed to a greater extent in FcRg
mice than in wild-type (wt) mice (Fig. 1B) , as previously reported for wt B16F10 metastases (12) . This difference was not due to different homing of tumor cells to the lungs after B16-luc2 + cell injection (Supplemental Fig. 1D , insert). mAb TA99, but not an isotype control mAb (Supplemental Fig.  1E ), reduced the tumor load in wt mice, but not in FcRg 2/2 mice (Fig. 1B) , an effect reliant on the FcRg ITAMs, as described previously (13) . Notably, the quantification of B16-luc2 + metastases using bioluminescence therefore reproduces data from previous studies using metastasis counts by eye (1, 6, 7), and may thus be applied to analyze the contribution of specific FcgRs to the mAb therapy of metastatic melanoma. CTX administration reduced the tumor load to a similar extent in both wt and FcRg 2/2 mice (Fig. 1B) . Importantly, the combination treatment (CTX+mAb TA99) was more efficient than the CTX treatment alone in wt mice, but not in FcRg 2/2 mice. The combination treatment, however, was not more efficient in wt mice than the administration of TA99 mAb alone. These results indicate that FcgRs contribute to both single mAb therapy and CTX+mAb combination therapy in this model. First, we examined the contribution of FcgRI to mAb TA99 therapy of B16-luc2 + metastases. Injection of B16-luc2 + cells led to similar tumor loads in wt and FcgRI 2/2 mice that were significantly reduced after mAb TA99 injections in both mouse strains (Fig. 1C) . The TA99-mediated reduction in tumor load was, however, less profound in FcgRI 2/2 mice compared with wt mice. This result indicates that FcgRI contributes to TA99-mediated reduction of B16 lung metastases, in accordance with the report by Bevaart et al. (7) . Although no contribution of FcgRI was identified by Nimmerjahn et al. (6) , our method of measuring tumor load may show in this study subtle differences that could not be revealed previously. To confirm our finding, we also investigated the contribution of FcgRI to this mAb therapy model in novel mice deficient for all IgG receptors except FcgRI (FcgRIIB/III/IV deficient). These "FcgRI-only" mice had partial reduction of tumor load after mAb TA99 injections (Fig. 1C) . Whereas the kinetics of tumor growth was similar in both types of mice, TA99-mediated reduction in tumor load tended to be less efficient in "FcgRI-only" mice than in wt mice (Supplemental Fig. 2A) . FcgRI therefore partially mediates the protective effect of mAb TA99.
We then reassessed the contribution of FcgRIV to this model. The injection of anti-FcgRIV mAbs had no significant effect on TA99-mediated tumor reduction in wt mice (Fig.  1D) , similar to its isotype control (Supplemental Fig. 2B ). Various FcgRIV-dependent disease models were abolished using the same dose of the same batch of anti-FcgRIV mAbs (data not shown and Refs. 8, 14) , indicating that FcgRIV was efficiently and systemically blocked in vivo. Notably, this mAb does not, by itself, induce FcgRIV-mediated cell activation in vitro (9) . Our in vivo result is unexpected because injections of the same dose of this blocking mAb were reported to partially impair the protective effect of TA99 (6) . To ascertain the lack of contribution of FcgRIV to this Ab
mice could be detected after mAb TA99 injections (Fig. 1E ). These results demonstrate that FcgRIV does not contribute to this model of Ab therapy, in agreement with results reported by Bevaart et al. (7) , but in contradiction to Nimmerjahn et al. (6) .
Considering that FcgRI contributes only partially to the reduction of tumor load (Fig. 1C) and because FcgRIV does not contribute (Fig. 1D, 1E) , we investigated whether the last mouse activating IgG receptor FcgRIII may contribute to TA99-mediated reduction of B16 lung metastases. mAb TA99 injections reduced tumor loads in both wt and FcgRIII 2/2 mice, but this effect was significantly impaired in FcgRIII 2/2 mice ( Fig. 2A) . This result is unexpected because it has been reported that wt and FcgRIII 2/2 mice display similar numbers/scores of B16 metastases after mAb TA99 injections (6, 7). To validate our finding, we took advantage of antiFcgRIII mAbs that we have described previously, which specifically block FcgRIII in vivo (8), and do not induce FcgRIII-mediated cell activation in vitro (Supplemental Fig.  2C, 2D ). Treatment with anti-FcgRIII mAb, but not isotype control, significantly impaired, but did not abolish, TA99-mediated reduction of tumor load in wt mice (Fig. 2B) . These results indicate that FcgRIII contributes to TA99-mediated therapy of B16 lung metastases.
Results obtained using FcgRI 2/2 mice or "FcgRI-only" mice (Fig. 1C, Supplemental Fig. 2A ), and FcgRIII 2/2 mice or anti-FcgRIII mAbs ( Fig. 2A, 2B) can be deduced to rely on the remaining activity of FcgRIII and FcgRI, respectively. Unfortunately, no mAb exists that blocks FcgRI to test this assumption in FcgRIII 2/2 mice. To investigate whether FcgRI and FcgRIII may be together responsible for TA99-mediated reduction in tumor load, we used mice expressing no activating IgG receptors except FcgRIV, "FcgRIV-only" mice (9) . These mice were unable to mediate TA99-mediated reduction in tumor load (Fig. 2C) . Furthermore, FcgRI 2/2 FcgRIIB 2/2 FcgRIII 2/2 tripledeficient mice were also unable to mediate the protective effect of mAb TA99 (data not shown).
Altogether, our results provide compelling evidence that FcgRI and FcgRIII are both responsible for the protective effect of anti-gp75 mAb on mouse B16 melanoma lung metastases. Using mice deficient for activating FcgRs, or blocking anti-FcgR mAbs, we identified a contribution by FcgRIII, reaffirmed the contribution of FcgRI (7), and by three different approaches excluded any contribution of FcgRIV to this immunotherapy model. Indeed, FcgRIII 2/2 mice and "FcgRIV-only" mice express higher levels of FcgRIV (5, 8, 15) ; however, these mice demonstrated reduced or undetectable TA99-mediated reduction in lung metastases load, also implying that FcgRIV does not contribute. Interestingly, it has been reported that the mAb TA99-mediated reduction of B16-F10 liver metastases relies on redundant functions of FcgRI and FcgRIV (16) , whereas that of B16-F10 solid s.c. tumors relies only on FcgRIV (5). In particular, the mAb TA99-mediated effect was unaffected in both reports in mice deficient for both FcgRI 2/2 and FcgRIII 2/2 . It remains to be determined why the s.c. solid tumor model relies on FcgRIV (5), the liver metastases model relies on either FcgRI or FcgRIV (16) , and the lung metastases model relies on additive roles of FcgRI and FcgRIII (this report), but these discrepancies may be explained by different effector populations mediating tumor clearance in skin, liver, and lung, respectively, and therefore on the IgG receptors they express. The contribution of FcgRI (CD64) to lung metastases clearance has been reported earlier (7) and is confirmed in this study using FcgRI 2/2 mice. Importantly, we demonstrate in this article for the first time, to our knowledge, that "FcgRIonly" mice retain the ability to reduce tumor load in this mAb therapy model. A role for FcgRIII (CD16) in contributing to metastases clearance was, however, unexpected based on previous reports (6, 7) but is supported by a report on the contribution of FcgRIII to the protective effect of anti-CD20 mAbs on the growth of CD20-expressing lymphoma (17) . In concordance with these results obtained in the mouse, polymorphisms in the gene encoding human FcgRIIIA (CD16A), the human functional homolog of mouse FcgRIII, indeed correlate with the therapeutic efficacy of rituximab (a chimeric anti-CD20 mAb) on non-Hodgkin's lymphoma (18) , and of trastuzumab (a humanized anti-HER-2 mAb) on HER-2 + metastatic breast cancer (19) . Two of our findings have important repercussions for the validity of the mouse as an animal model to study Ab-mediated cancer immunotherapy: 1) that FcgRs contribute to both single mAb therapy and combination (CTX+mAb) therapy; and 2) that mouse FcgRIII, like human FcgRIIIA, contributes to tumor clearance. Furthermore, our result supports the current trend in therapeutic Ab engineering of aiming to improve specific binding to human FcgRIIIA (CD16A) to increase Ab antitumor efficacy.
